Optinose reports Q2 EPS 2c vs (23c) last year

Reports Q2 revenue $19.454M vs $20.582M last year. “We are pleased with the progress we made in the second quarter of 2023 towards our strategic objectives,” stated CEO Ramy Mahmoud, MD, MPH. “That means we are outperforming our initial expectations for full year 2023 XHANCE net revenues while operating far more efficiently. It also means our effort to secure the first-ever drug approval for patients with chronic sinusitis is progressing towards the target goal date of December 16, 2023, and that we are effectively readying our organization for a successful launch. These objectives are preparing us, if our new indication is approved, to achieve rapid adoption for treatment of the tens of millions of chronic sinusitis patients in need of an effective medication.”